Journal of Vaccine Research 2024, Vol.14, No.2, 65-75
http://medscipublisher.com/index.php/jvr

Research Report Open Access

The Role of Adjuvants in Cancer Vaccine Development

Jianmin Liu
Sinovac Biotech Co., Ltd., Haiding, 100193, Beijing, China
Corresponding email: Jianminliu@sinovac.com
Journal of Vaccine Research, 2024, Vol.14, No.2 doi: 10.5376/jvr.2024.14.0008
Received: 18 Mar., 2024
Accepted: 22 Apr., 2024
Published: 03 May, 2024

Preferred citation for this article:
Liu J.M., 2024, The role of adjuvants in cancer vaccine development, Journal of Vaccine Research, 14(2): 65-75 (doi: 10.5376/jvr.2024.14.0008)

Abstract The study highlights several key findings regarding the use of adjuvants in cancer vaccines. Adjuvants such as Toll-like receptor agonists, saponins, and cytokines have been shown to significantly enhance the immune response by promoting antigen presentation and stimulating both innate and adaptive immunity. Novel adjuvants like QS-21 have demonstrated the ability to activate the NLRP3 inflammasome, leading to the release of cytokines crucial for Th1 responses, thereby improving vaccine efficacy. Additionally, combinatorial adjuvant strategies that target multiple branches of the immune response have been found to overcome obstacles related to antigen immunogenicity and tumor immune suppression. The use of adjuvants in conjunction with other treatments such as chemotherapy and radiotherapy has also been shown to enhance the overall immune response in a compromised environment. The findings underscore the critical role of adjuvants in the development of effective cancer vaccines. By enhancing antigen presentation and stimulating robust immune responses, adjuvants can significantly improve the efficacy of cancer vaccines. Future research should focus on optimizing adjuvant formulations and exploring novel adjuvant combinations to further enhance the therapeutic potential of cancer vaccines.
Keywords Cancer vaccines; Adjuvants; Immunogenicity; Immune response; Tumor antigens; QS-21, Toll-like receptor agonists; Combinatorial adjuvant strategies

1 Introduction

Cancer vaccines have emerged as a promising therapeutic strategy aimed at harnessing the body's immune system to target and eliminate cancer cells. Unlike traditional vaccines that prevent infectious diseases, cancer vaccines are designed to treat existing malignancies by stimulating an immune response against tumor-specific antigens. Over the past few decades, significant progress has been made in the development of therapeutic cancer vaccines, with various approaches being explored to enhance their efficacy (Bowen et al., 2018; Alarcon et al., 2022). Despite these advancements, the clinical success of cancer vaccines has been limited, primarily due to challenges such as poor immunogenicity of tumor antigens and the immunosuppressive tumor microenvironment (Vermaelen, 2019).

Adjuvants play a crucial role in the effectiveness of cancer vaccines. They are substances that enhance the body's immune response to an antigen, making the vaccine more effective. In the context of cancer vaccines, adjuvants are essential for overcoming the inherent challenges posed by the tumor microenvironment, such as immune evasion and suppression (Bowen et al., 2018; Vermaelen, 2019). Recent research has focused on developing novel adjuvants and combinatorial adjuvant strategies that can target multiple branches of the immune response, thereby improving the immunogenicity of tumor antigens and counteracting tumor-induced immune suppression (Bowen et al., 2018; Puth et al., 2022). For instance, pattern recognition receptor (PRR)-targeting adjuvants and their delivery platforms have shown promise in enhancing the efficacy of cancer vaccines (Alarcon et al., 2022).

This study explores the role of adjuvants in the development of effective cancer vaccines. By reviewing the current literature and recent advancements in adjuvant technology, this study aims to provide a comprehensive understanding of how adjuvants can be utilized to enhance the immune response against cancer. Specifically, the study will examine various classes of adjuvants, their mechanisms of action, and their potential to improve the clinical outcomes of cancer vaccine therapies. Through this investigation, we hope to identify key strategies that can be employed to overcome the existing challenges in cancer vaccine development and pave the way for more effective therapeutic interventions.

2 Mechanisms of Adjuvants

Adjuvants are critical components in vaccine formulations, particularly in cancer vaccines, as they enhance the body's immune response to the presented antigens. They work through various mechanisms, including the activation of innate immune responses, enhancement of antigen presentation, and modulation of the tumor microenvironment.

2.1 Enhancing immune response

Adjuvants enhance the immune response by stimulating antigen-presenting cells (APCs) such as dendritic cells (DCs) and macrophages. This activation leads to the production of cytokines and chemokines, which are crucial for the recruitment and activation of other immune cells, including T cells and B cells. For instance, the use of Toll-like receptor (TLR) agonists as adjuvants has been shown to significantly enhance cytokine secretion and improve antigen presentation, leading to robust cytotoxic T lymphocyte (CTL) responses (Kim et al., 2018; Chávez et al., 2020; Kocabaş et al., 2020; Luchner et al., 2021).

2.2 Types of adjuvants

Various types of adjuvants are used in cancer vaccine development, each with unique properties and mechanisms of action. The following sections discuss some of the most commonly used adjuvants.

2.2.1 Alum

Aluminum-based adjuvants, commonly referred to as alum, are among the oldest and most widely used adjuvants. They primarily enhance the immune response by promoting the uptake of antigens by APCs and stimulating the production of pro-inflammatory cytokines. Alum has been shown to be effective in enhancing humoral immunity, although its ability to stimulate cellular immunity is limited (Gonzalez-Lopez et al., 2019; Lee and Suresh, 2022).

2.2.2 Oil-in-water emulsions

Oil-in-water emulsions, such as MF59, are another class of adjuvants that have been used to enhance vaccine efficacy. These emulsions work by creating a depot effect at the injection site, which allows for a sustained release of the antigen. This prolonged exposure helps in the activation of APCs and the subsequent induction of both humoral and cellular immune responses (Lee and Suresh, 2022).

2.2.3 Toll-like receptor (TLR) agonists

TLR agonists are a promising class of adjuvants that target specific TLRs on immune cells, leading to the activation of innate immune responses. TLR agonists can be classified into cell surface TLRs (e.g., TLR1, TLR2, TLR4) and intracellular TLRs (e.g., TLR3, TLR7, TLR9). These adjuvants have been shown to enhance the production of pro-inflammatory cytokines and improve antigen presentation, thereby boosting both humoral and cellular immunity. For example, TLR3 agonists have been associated with extended survival in glioma patients when used in conjunction with dendritic cell vaccination (Antonios et al., 2020; Chávez et al., 2020; Luchner et al., 2021).

2.2.4 Saponins

Saponins are natural glycosides that have been used as adjuvants due to their ability to stimulate strong immune responses. They work by forming complexes with cholesterol in cell membranes, leading to the formation of pores that enhance antigen uptake by APCs. Saponin-based adjuvants, such as QS-21, have been shown to induce robust CTL responses and are being investigated for their potential in cancer vaccines (Lee and Suresh, 2022).

2.2.5 Cytokines and chemokines

Cytokines and chemokines are signaling molecules that play a crucial role in the regulation of immune responses. As adjuvants, they can be used to modulate the tumor microenvironment and enhance the recruitment and activation of immune cells. For instance, the use of cytokines such as interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF) has been shown to improve the efficacy of cancer vaccines by promoting the activation and proliferation of T cells (Kocabaş et al., 2020).

In conclusion, the use of adjuvants in cancer vaccine development is essential for enhancing the immune response and improving vaccine efficacy. Various types of adjuvants, including alum, oil-in-water emulsions, TLR agonists, saponins, and cytokines, have shown promise in preclinical and clinical studies, highlighting their potential in the fight against cancer.

3 Adjuvant Development and Optimization

3.1 Preclinical studies

Preclinical studies are crucial for the development and optimization of adjuvants in cancer vaccines. These studies often involve the use of animal models to evaluate the efficacy and safety of potential adjuvants. For instance, IL-7 has been identified as a promising adjuvant due to its role in the development, maintenance, and proliferation of T lymphocytes, which are essential for long-term immune memory against cancer (Zhao et al., 2022). Additionally, the use of multifunctional protein conjugates with built-in adjuvants has shown significant promise in preclinical models. These conjugates can enhance both humoral and cellular immune responses, suggesting a potential strategy for personalized antitumor immunotherapy (Du et al., 2020). Furthermore, the exploration of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) as adjuvants has opened new avenues for inducing strong and long-lasting immune responses in tumor immunity (Sun et al., 2021).

3.2 Clinical trials

Clinical trials are the next step in the development of adjuvants, where their safety and efficacy are tested in human subjects. A notable example is the phase II clinical trial for an adjuvant cancer-specific vaccine therapy for esophageal cancer patients. This trial demonstrated that the vaccine could improve survival rates, particularly in patients with specific tumor immune microenvironments (Yasuda et al., 2022). Another important aspect of clinical trials is the combination of adjuvants with other therapeutic agents to enhance the overall immune response. For example, combinatorial adjuvant strategies have been shown to overcome obstacles such as poor antigen immunogenicity and tumor immune suppression, thereby improving the efficacy of cancer vaccines (Bowen et al., 2018). The importance of adjuvants in personalized cancer vaccines has also been highlighted, emphasizing the need for strong adjuvants to increase the immunogenicity of peptide-based vaccines (Gouttefangeas and Rammensee, 2018).

3.3 Regulatory and safety considerations

Regulatory and safety considerations are paramount in the development of adjuvants for cancer vaccines. The safety profile of adjuvants must be thoroughly evaluated to ensure they do not cause severe toxic side effects. For instance, while many adjuvants can induce strong immune responses, their application is often limited by safety concerns (Hu and Li, 2020). Regulatory agencies require comprehensive data on the safety and efficacy of adjuvants before they can be approved for clinical use. This includes data from both preclinical and clinical studies. Additionally, the choice of adjuvants must take into account factors such as the age and health status of the patient, as these can influence the immune response (Cuzzubbo et al., 2021). The development of novel adjuvants that are both safe and effective remains a critical area of research in the field of cancer immunotherapy.

4 Innovative Approaches in Adjuvant Research

4.1 Novel adjuvant formulations

Recent advancements in adjuvant formulations have significantly enhanced the efficacy of cancer vaccines. One notable approach involves the use of bi-adjuvant nanovaccines, which combine multiple adjuvants to potentiate the immunogenicity of neoantigens. For instance, a bi-adjuvant nanovaccine incorporating Toll-like receptor (TLR) 7/8 agonist R848 and TLR9 agonist CpG has shown promising results in enhancing the immune response and reducing systemic toxicity, leading to significant tumor regression in preclinical models (Ni et al., 2020) (Figure 1). Additionally, the use of polyethyleneimine (PEI)-incorporated hollow mesoporous silica nanoparticles (HMSNs) has demonstrated improved antigen-loading efficacy and enhanced dendritic cell maturation, resulting in robust Th1 antitumor immunity and sustained immunological memory (Liu et al., 2019).



Figure 1 Combination of banNVs with immune checkpoint blockade markedly promoted the response rates and complete regression rates of MC38 tumors in syngeneic mice (Adopted from Ni et al., 2020)

Image caption: (A) Left: Experimental design for tumor immunotherapy in C57BL/6 mice with indicated formulations of vaccines (CpG: 2 nmol, R848: 8 μg, and Adpgk: 20 μg); middle: tumor growth curve, and right: mouse survival of C57BL/6 mice after subcutaneous inoculation with MC38 tumor cells (0.3×10^6) (n = 6 to 7 mice per group). (B) Left: Experimental design for combination tumor immunotherapy in C57BL/6 mice with banNVs and aPD-1 (CpG: 2 nmol, R848: 8 μg, Adpgk: 20 μg, and aPD-1: 200 μg); middle: tumor growth curve; and right: mouse survival of C57BL/6 mice after subcutaneous inoculation with MC38 tumor cells (0.3×10^6) (n = 5 to 7 mice per group). (C) Individual tumor growth and survival profile of C57BL/6 mice treated with vaccines and/or aPD-1 (CpG: 2 nmol, R848: 8 μg, Adpgk: 20 μg, and aPD-1: 200 μg) during 40 days (n = 5 to 7 mice per group). (D and E) Tumor growth curve after vaccination with banNVs or combination of banNV and aPD-1, together with lymphocyte depletion by anti-CD8, anti-CD4, or anti-NK1.1 (200 μg). All error bars show SEM. Data are represented as means ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 (one-way ANOVA with Bonferroni post hoc test and Student's t test) (Adopted from Ni et al., 2020)

4.2 Nanotechnology in adjuvant development

Nanotechnology has revolutionized the field of adjuvant development by enabling precise control over the physicochemical properties of adjuvants. Nanoplatforms can be engineered to enhance the delivery and presentation of antigens, thereby boosting the immune response. For example, the use of lipid-like materials in mRNA nanovaccines has facilitated efficient mRNA delivery and translation in dendritic cells, while simultaneously stimulating innate immune responses through TLR4 activation (Zhang and Xia, 2021). Furthermore, cancer cell membrane-coated nanoparticles modified with mannose have shown enhanced uptake by antigen-presenting cells and improved antitumor immune responses (Yang et al., 2018). Inorganic nanomaterials, such as gold nanoparticles, have also been employed to present adjuvants and antigens, significantly enhancing the immunogenicity of cancer vaccines (Li et al.,, 2018; Liu et al., 2021).

4.3 Personalized adjuvants

The development of personalized adjuvants tailored to individual patients' tumor profiles represents a cutting-edge approach in cancer vaccine research. Personalized cancer vaccines, which incorporate patient-specific tumor antigens, have shown promise in eliciting robust antitumor immune responses. However, the success of these vaccines heavily relies on the use of potent adjuvants to overcome tumor-induced immunosuppression and enhance immunogenicity. For instance, personalized mRNA cancer vaccines formulated with lipid-like materials have demonstrated significant antitumor efficacy by efficiently delivering tumor antigens and stimulating T cell

activation (Zhang and Xia, 2021). Additionally, the use of combinatorial adjuvant strategies targeting multiple branches of the immune response has been proposed to address the challenges of poor antigen immunogenicity and tumor immune evasion (Bowen et al., 2018).

In conclusion, innovative approaches in adjuvant research, including novel formulations, nanotechnology-based adjuvants, and personalized adjuvants, are paving the way for the development of more effective cancer vaccines. These advancements hold great potential for improving the immunogenicity and therapeutic efficacy of cancer vaccines, ultimately leading to better clinical outcomes for patients.

5 Application of Adjuvants in Cancer Vaccine Development

Adjuvants play a crucial role in enhancing the efficacy of cancer vaccines by boosting the immune response against tumor-associated antigens. This section explores the various applications of adjuvants in cancer vaccine development, focusing on enhancing antigen immunogenicity, modulating the tumor microenvironment, and their use in combination therapies.

5.1 Enhancing antigen immunogenicity

One of the primary challenges in cancer vaccine development is the poor immunogenicity of tumor antigens. Adjuvants can significantly enhance the immunogenicity of these antigens, leading to a more robust immune response. For instance, the use of Toll-like receptor (TLR) agonists as adjuvants has been shown to improve the activation and proliferation of cytotoxic T lymphocytes (CTLs), which are crucial for targeting and destroying cancer cells (Gouttefangeas and Rammensee, 2018; Yoshida et al., 2019). Additionally, novel adjuvant formulations, such as CpG nanoadjuvants, have been developed to promote antigen presentation and amplify immune responses by co-delivering antigens and adjuvants (Yang et al., 2021).

5.2 Modulating tumor microenvironment

The tumor microenvironment (TME) is often immunosuppressive, which hinders the effectiveness of cancer vaccines. Adjuvants can modulate the TME to create a more favorable environment for immune responses. For example, L-ergothioneine (EGT) combined with TLR2 ligands has been shown to reduce the immunosuppressive functions of tumor-associated macrophages (TAMs), thereby enhancing the efficacy of cancer vaccines (Yoshida et al., 2019). Similarly, Zn2+-doped layered double hydroxide (Zn-LDH) adjuvants can neutralize the acidic TME and promote a pro-inflammatory network, which includes M1-TAMs, cytotoxic T cells, and natural killer cells, thereby enhancing antitumor immunity (Zhang et al., 2022).

5.3 Combination therapies

Combining adjuvants with other therapeutic strategies can further enhance the efficacy of cancer vaccines. For instance, the combination of photodynamic therapy (PDT) with CpG adjuvants has been shown to boost antitumor immune responses by generating tumor-associated antigens and initiating strong immune responses (Cai et al., 2020). Additionally, the use of dual-adjuvant systems, such as pH-sensitive liposomes loaded with STING and TLR9 agonists, has demonstrated significant tumor regression by enhancing Th1 immune responses and reversing the immunosuppressive TME (Kocabaş et al., 2020). These combination therapies highlight the potential of adjuvants to synergize with other treatments, leading to improved clinical outcomes.

In conclusion, adjuvants are indispensable in cancer vaccine development, offering multiple benefits such as enhancing antigen immunogenicity, modulating the tumor microenvironment, and enabling effective combination therapies. Continued research and development of novel adjuvant strategies will be essential for overcoming the current challenges in cancer immunotherapy and achieving better therapeutic success.

6 Case Studies of Adjuvants in Cancer Vaccines

6.1 Provenge (Sipuleucel-T)

Provenge (Sipuleucel-T) is the first FDA-approved therapeutic cancer vaccine, designed to treat prostate cancer. It leverages the patient's own immune cells, which are collected and exposed to a protein found in most prostate cancers, combined with an immune-stimulating agent. This process aims to stimulate the body's immune system

to attack prostate cancer cells. The success of Provenge has paved the way for further research into the use of adjuvants in cancer vaccines, highlighting the importance of personalized immunotherapy in oncology (Li et al., 2022).

6.2 HPV vaccines (Cervarix, Gardasil)

Cervarix and Gardasil are prophylactic vaccines designed to prevent infections by human papillomavirus (HPV), which is linked to cervical cancer and other HPV-related diseases. Both vaccines have shown high efficacy in inducing long-lasting immune responses. Cervarix, which contains the AS04 adjuvant, has been found to induce higher and more persistent antibody responses compared to Gardasil, which uses an aluminum-based adjuvant (Godi et al., 2019; Lehtinen et al., 2020; Nicoli et al., 2020). The AS04 adjuvant in Cervarix enhances the immune response by stimulating both the innate and adaptive immune systems, providing cross-protection against non-vaccine HPV types (Lehtinen et al., 2020; Matsumura et al., 2023) (Figure 2).



Figure 2 Scientific evaluation of macrophagic myofasciitis (MFF) (Adopted from Matsumura et al., 2023)

Image caption: Some vaccines contain aluminum (Al) hydroxide as an adjuvant, enhancing immune responses to antigens. Following intramuscular vaccination in the deltoid muscle, macrophages phagocytose Al-adsorbed antigens and present antigens to lymphocytes. (Top) Subsequently, the local inflammation induced by the vaccination is subsided, and macrophages and a few lymphocytes could be seen as scar or a "vaccination tattoo" in the deltoid muscle. (Middle) When autoimmune diseases or microbial infections occur, pro-inflammatory cytokine levels in sera can be increased, activating pre-existing infiltrated macrophages in the deltoid muscle in a bystander fashion ("bystander activation"); Al-containing activated macrophages can be observed as MMF pathology. Here, MMF is the result of systemic inflammation. (Bottom) Authier's group proposed that the vaccination with an Al-containing vaccine causes pathological inflammation composed of macrophages with Al in the cytoplasm in the deltoid muscle by, as yet, an unknown mechanism. Although MMF pathology is localized at the deltoid, this leads to diffuse myalgia at the upper and lower extremities, and sometimes can cause autoimmune diseases, such as multiple sclerosis by, as yet, an unknown mechanism. Here, MMF is the cause of autoimmune diseases (Adopted from Matsumura et al., 2023)

6.3 Experimental vaccines

Experimental cancer vaccines are being developed to target various types of cancers using different adjuvants to enhance their efficacy. For instance, a study on a mannose receptor-targeting nano-adjuvant combined with a peptide vaccine showed promising results in a murine model of HPV-induced cervical cancer. This nano-adjuvant, which includes a toll-like receptor agonist, significantly improved antitumor immunity by targeting antigen-presenting cells and reducing immunosuppressive cells in the tumor microenvironment (Mohapatra et al., 2023). Another experimental approach involves the use of a black phosphorus nanosheet-based nanovaccine, which has demonstrated strong antigen-specific T-cell responses and antitumor effects in preclinical studies (Li et al., 2022). These innovative adjuvant strategies are crucial for the development of effective therapeutic cancer vaccines.

7 Challenges and Future Directions

7.1 Improving adjuvant efficacy

One of the primary challenges in cancer vaccine development is the poor immunogenicity of tumor antigens and the ability of tumors to evade immune detection. To address this, adjuvants must be designed to enhance the immune response effectively. Multi-adjuvant strategies that target various branches of the immune system have shown promise in overcoming these obstacles. For instance, combining adjuvants that stimulate both humoral and cellular responses can significantly improve vaccine efficacy (Bowen et al., 2018; Du et al., 2020). Additionally, novel adjuvants such as Toll-like receptor (TLR) agonists and saponin-based adjuvants have been shown to enhance dendritic cell cross-presentation, which is crucial for activating cytotoxic T cells (Ho et al., 2018; Reed et al., 2009). Future research should focus on optimizing these combinations and understanding their mechanisms to develop more potent adjuvants.

7.2 Personalized cancer vaccines

Personalized cancer vaccines represent a promising direction in cancer immunotherapy. These vaccines are tailored to the unique antigenic profile of an individual's tumor, potentially leading to more effective immune responses. The development of personalized vaccines involves identifying neoantigens through bioinformatics and incorporating them into vaccine formulations along with potent adjuvants (Gouttefangeas and Rammensee, 2018; Abd-Aziz and Poh, 2022). However, challenges remain in the scalability and cost-effectiveness of producing personalized vaccines. Moreover, the selection of appropriate adjuvants that can work synergistically with personalized antigens is critical. Research should aim to streamline the production processes and identify adjuvants that can enhance the efficacy of personalized vaccines without increasing toxicity (Du et al., 2020; Alarcon et al., 2022).

7.3 Novel adjuvant discoveries

The discovery of new adjuvants is essential for the advancement of cancer vaccines. Current adjuvants, such as aluminum-based nanoparticles and MPL (mono-phosphoryl lipid A), have limitations in terms of safety and efficacy (Reed et al., 2009; Verma et al., 2023). Novel adjuvants that can stimulate both innate and adaptive immune responses are needed. For example, adjuvants that target pattern recognition receptors (PRRs) have shown potential in enhancing immune responses against cancer (Alarcon et al., 2022). Additionally, the use of multifunctional protein conjugates with built-in adjuvants has demonstrated significant improvements in immune responses and reduced systemic toxicity (Du et al., 2020). Future research should focus on identifying and characterizing new adjuvants, understanding their mechanisms of action, and evaluating their safety and efficacy in clinical trials (Cuzzubbo et al., 2021; Verma et al., 2023).

In conclusion, while significant progress has been made in the development of cancer vaccine adjuvants, several challenges remain. Improving adjuvant efficacy, developing personalized cancer vaccines, and discovering novel adjuvants are critical areas that require further research and innovation. By addressing these challenges, we can enhance the effectiveness of cancer vaccines and bring us closer to achieving successful cancer immunotherapy.

8 Concluding Remarks

The development of effective cancer vaccines remains a significant challenge due to the poor immunogenicity of tumor antigens and the complex mechanisms of tumor immune evasion. Adjuvants play a crucial role in enhancing the efficacy of these vaccines by stimulating robust and long-lasting immune responses. Various strategies have been explored to improve adjuvant efficacy, including the use of combination adjuvants that target multiple branches of the immune response. The incorporation of immunostimulants such as Toll-like receptor agonists, saponins, and cytokines has shown promise in overcoming the limitations of traditional adjuvants. Additionally, novel approaches like the use of IL-7 to maintain T cell memory and the development of multifunctional protein conjugates with built-in adjuvants have demonstrated significant potential in pre-clinical and clinical settings. The role of dendritic cells in cross-presentation and the use of particulate carrier systems to co-deliver antigens and adjuvants have also been highlighted as key factors in enhancing vaccine potency.

Future research should focus on optimizing adjuvant combinations to maximize immune responses while minimizing side effects. The exploration of less conventional adjuvants, such as those derived from exercise, diet, and psychological care, could provide new avenues for enhancing vaccine efficacy in older adults and those with compromised immune systems. Advances in bioinformatics for the identification of tumor neoantigens and the development of targeted delivery platforms for adjuvants will be critical in the design of next-generation cancer vaccines. Furthermore, the potential of PAMPs and DAMPs as new adjuvants warrants further investigation to understand their mechanisms and optimize their use in vaccine formulations. The integration of these novel adjuvants with existing immunotherapies, such as checkpoint inhibitors, could lead to more effective and personalized cancer treatments.

The successful development of adjuvants that can effectively enhance the immune response to cancer vaccines has significant implications for cancer treatment. By improving the immunogenicity of tumor antigens and overcoming tumor immune evasion mechanisms, these adjuvants can lead to more effective and durable anti-tumor responses. The use of multifunctional protein conjugates and particulate carrier systems can further enhance the delivery and efficacy of cancer vaccines, potentially reducing the need for high doses and minimizing systemic side effects. As our understanding of the tumor microenvironment and immune responses continues to grow, the integration of advanced adjuvant strategies into cancer vaccine development holds promise for improving patient outcomes and advancing the field of cancer immunotherapy.

Acknowledgments

Thank you to the peer reviewers for their valuable feedback.

Conflict of Interest Disclosure

The author affirms that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.

References

Abd-Aziz N., and Poh C.L., 2022, Development of peptide‐based vaccines for cancer, Journal of Oncology, 2022(1): 9749363.
https://doi.org/10.1155/2022/9749363
PMid:35342400 PMCid:PMC8941562

Alarcon N.O., Jaramillo M., Mansour H.M., and Sun B., 2022, Therapeutic cancer vaccines-antigen discovery and adjuvant delivery platforms, Pharmaceutics, 14(7): 1448.
https://doi.org/10.3390/pharmaceutics14071448
PMid:35890342 PMCid:PMC9325128

Antonios J.P., Everson R.G., Mochizuki A., Khattab S., Soto H., Romiyo P., Sun M., Moughon D., Billingslea-Yoon E., Odesa S., Li G., Kawaguchi E., Salazar A., Yong W., Schlossman J., Ellingson B., Wang A., Cloughesy T., Prins R., and Liau L.M., 2020, Abstract PR13: Adjuvant TLR-3 administration enhances proinflammatory immune responses and is associated with extended survival in glioblastoma patients treated with dendritic cell vaccination, Cancer Immunology Research, 8(3_Supplement): PR13-PR13.
https://doi.org/10.1158/2326-6074.TUMIMM19-PR13

Bowen W.S., Svrivastava A.K., Batra L., Barsoumian H., and Shirwan H., 2018, Current challenges for cancer vaccine adjuvant development, Expert Review of Vaccines, 17(3): 207-215.
https://doi.org/10.1080/14760584.2018.1434000
PMid:29372660 PMCid:PMC6093214

Cai Z., Xin F., Wei Z., Wu M., Lin X., Du X., Chen G., Zhang D., Zhang Z., Liu X., and Yao C., 2020, Photodynamic therapy combined with antihypoxic signaling and CpG adjuvant as an in situ tumor vaccine based on Metal-Organic framework nanoparticles to boost cancer immunotherapy, Advanced Healthcare Materials, 9(1): 1900996.
https://doi.org/10.1002/adhm.201900996
PMid:31746153

Chavez C., Everson R., Orpilla J., Lee A., Khattab S., Antonios J., Salazar A., Cloughesy T., Liau L., Sun L., Hugo W., and Prins R., 2020, CTIM-18. dendritic cell vaccination in conjunction with adjuvant tlr-3 agonist administration enhances pro-inflammatory immune responses and is associated with extended survival in malignant glioma patients, Neuro-Oncology, (Suppl 2): ii36.
https://doi.org/10.1093/neuonc/noaa215.152
PMCid:PMC7650313

Cuzzubbo S., Mangsbo S., Nagarajan D., Habra K., Pockley A.G., and McArdle S.E., 2021, Cancer vaccines: Adjuvant potency, importance of age, lifestyle, and treatments, Frontiers in Immunology, 11: 615240.
https://doi.org/10.3389/fimmu.2020.615240
PMid:33679703 PMCid:PMC7927599

Du J.J., Wang C.W., Xu W.B., Zhang L., Tang Y.K., Zhou S.H., Gao X., Yang G., and Guo J., 2020, Multifunctional protein conjugates with built-in adjuvant (adjuvant-protein-antigen) as cancer vaccines boost potent immune responses, Iscience, 23(3).
https://doi.org/10.1016/j.isci.2020.100935
PMid:32146328 PMCid:PMC7063246

Godi A., Panwar K., Haque M., Cocuzza C.E., Andrews N., Southern J., Turner P., Miller E., and Beddows S., 2019, Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine, Vaccine, 37(18): 2455-2462.
https://doi.org/10.1016/j.vaccine.2019.03.052
PMid:30926298

Gonzalez-Lopez A., Oostendorp J., Koernicke T., Fadini T., D'Oro U., Baker S., O'hagan D., Giudice G., Siena E., Finco O., and Medini D., 2019, Adjuvant effect of TLR7 agonist adsorbed on aluminum hydroxide (AS37): a phase I randomized, dose escalation study of an AS37-adjuvanted meningococcal C conjugated vaccine, Clinical Immunology, 209: 108275.
https://doi.org/10.1016/j.clim.2019.108275
PMid:31669193

Gouttefangeas C., and Rammensee H.G., 2018, Personalized cancer vaccines: adjuvants are important, too, Cancer Immunology, Immunotherapy, 67(12): 1911-1918.
https://doi.org/10.1007/s00262-018-2158-4
PMid:29644387 PMCid:PMC11028305

Ho N.I., Huis in't Veld L.G., Raaijmakers T.K., and Adema G.J., 2018, Adjuvants enhancing cross-presentation by dendritic cells: the key to more effective vaccines?, Frontiers in Immunology, 9: 2874.
https://doi.org/10.3389/fimmu.2018.02874
PMid:30619259 PMCid:PMC6300500

Hu H.G., and Li Y.M., 2020, Emerging adjuvants for cancer immunotherapy, Frontiers in Chemistry, 8: 601.
https://doi.org/10.3389/fchem.2020.00601
PMid:32850636 PMCid:PMC7406886

Kim H., Niu L., Larson P., Kucaba T.A., Murphy K.A., James B.R., Ferguson D., Griffith T., and Panyam J., 2018, Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy, Biomaterials, 164: 38-53.
https://doi.org/10.1016/j.biomaterials.2018.02.034
PMid:29482062

Kocabaş B.B., Almacioglu K., Bulut E.A., Gucluler G., Tincer G., Bayik D., Gursel M., and Gursel I., 2020, Dual-adjuvant effect of pH-sensitive liposomes loaded with STING and TLR9 agonists regress tumor development by enhancing Th1 immune response, Journal of Controlled Release, 328: 587-595.
https://doi.org/10.1016/j.jconrel.2020.09.040
PMid:32971199

Lee W., and Suresh M., 2022, Vaccine adjuvants to engage the cross-presentation pathway, Frontiers in Immunology, 13: 940047.
https://doi.org/10.3389/fimmu.2022.940047
PMid:35979365 PMCid:PMC9376467

Lehtinen M., Apter D., Eriksson T., Harjula K., Hokkanen M., Lehtinen T., Natunen K., Damaso S., Soila M., Bi D., and Struyf F., 2020, Effectiveness of the AS04 - adjuvanted HPV - 16/18 vaccine in reducing oropharyngeal HPV infections in young females-Results from a community - randomized trial, International Journal of Cancer, 147(1): 170-174.
https://doi.org/10.1002/ijc.32791
PMid:31736068 PMCid:PMC7318585

Li W.H., Su J.Y., and Li Y.M., 2022, Rational design of T-cell-and B-cell-based therapeutic cancer vaccines, Accounts of Chemical Research, 55(18): 2660-2671.
https://doi.org/10.1021/acs.accounts.2c00360
PMid:36048514

Li X., Wang X., and Ito A., 2018, Tailoring inorganic nanoadjuvants towards next-generation vaccines, Chemical Society Reviews, 47(13): 4954-4980.
https://doi.org/10.1039/C8CS00028J
PMid:29911725

Liu Q., Zhou Y., Li M., Zhao L., Ren J., Li D., Tan Z., Wang K., Li H., Hussain M., Zhang L., Shen G., Zhu J., and Tao J., 2019, Polyethylenimine hybrid thin-shell hollow mesoporous silica nanoparticles as vaccine self-adjuvants for cancer immunotherapy, ACS Applied Materials and Interfaces, 11(51): 47798-47809.
https://doi.org/10.1021/acsami.9b19446
PMid:31773941

Liu Y., Wang Z., Yu F., Li M., Zhu H., Wang K., Meng M., and Zhao W., 2021, The adjuvant of α-galactosylceramide presented by gold nanoparticles enhances antitumor immune responses of MUC1 antigen-based tumor vaccines, International Journal of Nanomedicine, 403-420.
https://doi.org/10.2147/IJN.S273883
PMid:33469292 PMCid:PMC7813472

Luchner M., Reinke S., and Milicic A., 2021, TLR agonists as vaccine adjuvants targeting cancer and infectious diseases, Pharmaceutics, 13(2): 142.
https://doi.org/10.3390/pharmaceutics13020142
PMid:33499143 PMCid:PMC7911620

Matsumura N., Shiro R., and Tsunoda I., 2023, Critical evaluation on roles of macrophagic myofasciitis and aluminum adjuvants in HPV vaccine-induced adverse events, Cancer Science, 114(4): 1218-1228.
https://doi.org/10.1111/cas.15714
PMid:36601818 PMCid:PMC10067403

Mohapatra A., Rajendrakumar S.K., Cherukula K., Park M.S., Padmanaban S., Vasukuty A., Mohanty A., Lee J., Bae W., and Park I.K., 2023, A sugar modified amphiphilic cationic nano-adjuvant ceased tumor immune suppression and rejuvenated peptide vaccine induced antitumor immunity in cervical cancer, Biomaterials Science, 11(5): 1853-1866.
https://doi.org/10.1039/D2BM01715F
PMid:36655902

Ni Q., Zhang F., Liu Y., Wang Z., Yu G., Liang B., Niu G., Su T., Zhu G., Lu G., Zhang L., and Chen X., 2020, A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer, Science Advances, 6(12): eaaw6071.
https://doi.org/10.1126/sciadv.aaw6071
PMid:32206706 PMCid:PMC7080439

Nicoli F., Mantelli B., Gallerani E., Telatin V., Bonazzi I., Marconi P., Gavioli R., Gabrielli L., Lazzarotto T., Barzon L., Palù G., and Caputo A., 2020, HPV-specific systemic antibody responses and memory B cells are independently maintained up to 6 years and in a vaccine-specific manner following immunization with Cervarix and Gardasil in adolescent and young adult women in vaccination programs in Italy, Vaccines, 8(1): 26.
https://doi.org/10.3390/vaccines8010026
PMid:31947611 PMCid:PMC7175219

Puth S., Verma V., Hong S.H., Tan W., Lee S.E., and Rhee J.H., 2022, An all-in-one adjuvanted therapeutic cancer vaccine targeting dendritic cell cytosol induces long-lived tumor suppression through NLRC4 inflammasome activation, Biomaterials, 286: 121542.
https://doi.org/10.1016/j.biomaterials.2022.121542
PMid:35594837

Reed S.G., Bertholet S., Coler R.N., and Friede M., 2009, New horizons in adjuvants for vaccine development, Trends in Immunology, 30(1): 23-32.
https://doi.org/10.1016/j.it.2008.09.006
PMid:19059004

Sun H., Hu W., Yan Y., Zhang Z., Chen Y., Yao X., Teng L., Wang X., Chai D., Zheng J., and Wang G., 2021, Using PAMPs and DAMPs as adjuvants in cancer vaccines. Human Vaccines and Immunotherapeutics, 17(12): 5546-5557.
https://doi.org/10.1080/21645515.2021.1964316
PMid:34520322 PMCid:PMC8903972

Verma S.K., Mahajan P., Singh N.K., Gupta A., Aggarwal R., Rappuoli R., and Johri A.K., 2023, New-age vaccine adjuvants, their development, and future perspective, Frontiers in Immunology, 14: 1043109.
https://doi.org/10.3389/fimmu.2023.1043109
PMid:36911719 PMCid:PMC9998920

Vermaelen K., 2019, Vaccine strategies to improve anti-cancer cellular immune responses, Frontiers in Immunology, 10: 8.
https://doi.org/10.3389/fimmu.2019.00008
PMid:30723469 PMCid:PMC6349827

Yang A., Bai Y., Dong X., Ma T., Zhu D., Mei L., and Lv F., 2021, Hydrogel/nanoadjuvant-mediated combined cell vaccines for cancer immunotherapy, Acta Biomaterialia, 133: 257-267.
https://doi.org/10.1016/j.actbio.2021.08.014
PMid:34407475

Yang R., Xu J., Xu L., Sun X., Chen Q., Zhao Y., Peng R., and Liu Z., 2018, Cancer cell membrane-coated adjuvant nanoparticles with mannose modification for effective anticancer vaccination, ACS nano, 12(6): 5121-5129.
https://doi.org/10.1021/acsnano.7b09041
PMid:29771487

Yasuda T., Nishiki K., Hiraki Y., Kato H., Iwama M., Shiraishi O., Yasuda A., Shinkai M., Kimura Y., Sukegawa Y., Chiba Y., Imano M., Takeda K., Satou T., Shiozaki H., and Nakamura Y., 2022, Phase II adjuvant cancer-specific vaccine therapy for esophageal cancer patients curatively resected after preoperative therapy with pathologically positive nodes; possible significance of tumor immune microenvironment in its clinical effects, Annals of Surgery, 275(1): e155-e162.
https://doi.org/10.1097/SLA.0000000000003880
PMid:33055588

Yoshida S., Shime H., Matsumoto M., Kasahara M., and Seya T., 2019, Anti-oxidative amino acid L-ergothioneine modulates the tumor microenvironment to facilitate adjuvant vaccine immunotherapy, Frontiers in Immunology, 10: 671.
https://doi.org/10.3389/fimmu.2019.00671
PMid:31019508 PMCid:PMC6458301

Zhang H., and Xia X., 2021, RNA cancer vaccines: developing mRNA nanovaccine with self-adjuvant property for cancer immunotherapy, Human Vaccines and Immunotherapeutics, 17(9): 2995-2998.
https://doi.org/10.1080/21645515.2021.1921524
PMid:33945399 PMCid:PMC8381784

Zhang L., Zhao J., Hu X., Wang C., Jia Y., Zhu C., Xie S., Lee J., Li F., and Ling D., 2022, A peritumorally injected immunomodulating adjuvant elicits robust and safe metalloimmunotherapy against solid tumors, Advanced Materials, 34(41): 2206915.
https://doi.org/10.1002/adma.202206915
PMid:35986645

Zhao Y., Wei K., Chi H., Xia Z., and Li X., 2022, IL-7: A promising adjuvant ensuring effective T cell responses and memory in combination with cancer vaccines?, Frontiers in Immunology, 13: 1022808.
https://doi.org/10.3389/fimmu.2022.1022808
PMid:36389666 PMCid:PMC9650235